Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures (original) (raw)

• Bendandi, M. Anti-idiotype vaccines for human follicular lymphoma. Leukemia 14, 1333–1339 (2000).
  Article CAS PubMed Google Scholar
• Stevenson, G. K. & Stevenson, F. K. Antibody to a molecularly-defined antigen confined to a tumor cell surface. Nature 254, 714–716 (1974).
  Article Google Scholar
• Baskar, S., Kobrin, C. B. & Kwak, L. W. Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes. J. Clin. Invest. 113, 1498–1510 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Bendandi, M. Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma. Expert Rev. Anticancer Ther. 1, 65–72 (2001).
  Article CAS PubMed Google Scholar
• Bendandi, M. The role of idiotype vaccines in the treatment of human B-cell malignancies. Expert Rev. Vaccines 3, 163–170 (2004).
  Article CAS PubMed Google Scholar
• Dave, S. S. et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med. 351, 2159–2169 (2004).
  Article CAS PubMed Google Scholar
• Bendandi, M. Aiming at a clinical strategy for follicular lymphoma. CA Cancer J. Clin. 58, 305–317 (2008).
  Article PubMed Google Scholar
• Lynch, R. G., Graff, R. J., Sirisinha, S., Simms, E. S. & Eisen, H. N. Myeloma proteins as tumor-specific transplantation antigens. Proc. Natl Acad. Sci. USA 69, 1540–1544 (1972).
  Article CAS Google Scholar
• Kaminski, M. S., Kitamura, K., Maloney, D. G. & Levy, R. Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J. Immunol. 138, 1289–1296 (1987).
  CAS PubMed Google Scholar
• Kwak, L. W., Young, H. A., Pennington, R. W. & Weeks, S. D. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T cell response. Proc. Natl Acad. Sci. USA 93, 10972–10977 (1996).
  Article CAS Google Scholar
• Hsu, F. J. et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma — long-term results of a clinical trial. Blood 89, 3129–3135 (1997).
  CAS PubMed Google Scholar
• Bendandi, M. et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nature Med. 5, 1171–1177 (1999).
  Article CAS Google Scholar
• Redfern, C. H. et al. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J. Clin. Oncol. 24, 3107–3112 (2006).
  Article CAS PubMed Google Scholar
• Inogés, S. et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J. Natl Cancer Inst. 98, 1292–1301 (2006).
  Article PubMed Google Scholar
• Yáñez, R. et al. Anti-idiotypic immunotherapy in follicular lymphoma patients: results of a long follow-up study. J. Immunother. 31, 310–312 (2008).
  Article PubMed Google Scholar
• Inogés, S. et al. Prolonged idiotypic vaccination against follicular lymphoma. Leuk. Lymphoma 50, 47–53 (2009).
  Article PubMed Google Scholar
• Bendandi, M. Clinical benefit of idiotype vaccines: too many trials for a clever demonstration? Rev. Recent Clin. Trials 1, 67–74 (2006).
  Article CAS PubMed Google Scholar
• Freedman, A. et al. Placebo-controlled Phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J. Clin. Oncol. 27, 3036–3043 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Sirisinha, S. & Eisen, H. N. Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins. Proc. Natl Acad. Sci. USA 68, 3130–3135 (1971).
  Article CAS Google Scholar
• Longo, D. L. Idiotype vaccination in follicular lymphoma: knocking on the doorway to cure. J. Natl Cancer Inst. 98, 1263–1265 (2006).
  Article PubMed Google Scholar
• Harris, J. R. & Markl, J. Keyhole limpet hemocyanin: molecular structure of a potent marine immunoactivator. A review. Eur. Urol. 37 (Suppl. 3), 24–33 (2000).
  Article CAS PubMed Google Scholar
• Ai, W. Z., Tibshirani, R., Taidi, B., Czerwinski, D. K. & Levy, R. Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma. Blood 113, 5743–5746 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Kwak, L. W. et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327, 1209–1215 (1992).
  Article CAS PubMed Google Scholar
• Johnson, P. W. M. et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J. Clin. Oncol. 13, 140–147 (1995).
  Article CAS PubMed Google Scholar
• de Cerio, A. L. & Inogés, S. Future of idiotypic vaccination for B-cell lymphoma. Expert Rev. Vaccines 8, 43–50 (2009).
  Article PubMed Google Scholar
• Houot, R. & Levy, R. Vaccines for lymphomas: idiotype vaccines and beyond. Blood Rev. 23, 137–142 (2009).
  Article CAS PubMed Google Scholar
• Twombly, R. First proteasome inhibitor approved for multiple myeloma. J. Natl Cancer Inst. 95, 845 (2006).
  Article Google Scholar
• Richardson, P. G. et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348, 2609–2617 (2003).
  CAS PubMed Google Scholar
• Cheson, B. D. et al. Revised response criteria for malignant lymphoma. J. Clin. Oncol. 25, 579–586 (2007).
  Article PubMed Google Scholar
• Levy, R. et al. Results of a phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin's lymphoma (fNHL). Proc. Am. Assoc. Cancer Res. Abstr. LB–204 (2008).
• Harris, N. L. et al. in WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (eds Swerdlow, S. H. et al.) 220–226 (IARC, Lyon, 2008).
  Google Scholar
• Schuster, S. J. et al. Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results. J. Clin. Oncol. Abstr. 27, S15 (2009).
  Article Google Scholar
• Raffeld, M., Neckers, L., Longo, D. L. & Cossman, J. Spontaneous alteration of idiotype in a monoclonal B-cell lymphoma. Escape from detection by anti-idiotype. N. Engl. J. Med. 312, 1653–1658 (1985).
  Article CAS PubMed Google Scholar
• Meeker, T. et al. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N. Engl. J. Med. 312, 1658–1665 (1985).
  Article CAS PubMed Google Scholar
• Park, H. J. & Neelapu, S. S. Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials. Br. J. Haematol. 142, 179–191 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Carroll, W. L., Thielemans, K., Dilley, J. & Levy, R. Mouse x human heterohybridomas as fusion partners with human B-cell tumors. J. Immunol. Methods 89, 61–72 (1986).
  Article CAS PubMed Google Scholar
• Rodríguez-Calvillo, M. et al. Variations in “rescuability” of immunoglobulin molecules from different forms of human lymphoma: implications for antiidiotype vaccine development. Crit. Rev. Oncol. Hematol. 52, 1–7 (2004).
  Article PubMed Google Scholar
• Zhu, D. et al. Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. Blood 99, 2562–2568 (2002).
  Article CAS PubMed Google Scholar
• Zabalegui, N. et al. Acquired potential N-glycosylation sites within the tumor-specific heavy chains of B-cell malignancies. Haematologica 89, 541–546 (2004).
  CAS PubMed Google Scholar
• Radcliffe, C. M. et al. Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor. J. Biol. Chem. 282, 7405–7415 (2007).
  Article CAS PubMed Google Scholar
• Betting, D. J. et al. Enhanced immune stimulation by a therapeutic lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cells. Vaccine 27, 250–259 (2009).
  Article CAS PubMed Google Scholar
• Timmerman, J. M. et al. Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin's lymphoma. Leuk. Lymphoma 50, 37–46 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Houot, R. & Levy, R. Idiotype vaccination for lymphoma: moving towards optimization. Leuk. Lymphoma 50, 1–2 (2009).
  Article PubMed Google Scholar
• Betting, D. J., Kafi, K., Abdollahi-Fard, A., Hurvitz, S. A. & Timmerman, J. M. Sulfhydril-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B-cell lymphomas. J. Immunol. 181, 4131–4140 (2008).
  Article CAS PubMed Google Scholar
• Kafi, K. et al. Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines. Mol. Immunol. 46, 448–456 (2009).
  Article CAS PubMed Google Scholar
• Biragyn, A. et al. Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. Blood 104, 1961–1969 (2004).
  Article CAS PubMed Google Scholar
• Davis, T. A., Maloney, D. G., Czerwinski, D. K., Liles, T. M. & Levy, R. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood 92, 1184–1190 (1998).
  CAS PubMed Google Scholar
• George, A. J., Tutt, A. L. & Stevenson, F. K. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1. J. Immunol. 138, 628–634 (1987).
  CAS PubMed Google Scholar
• Campbell, M. J., Esserman, L., Byars, N. E., Allison, A. C. & Levy, R. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor activity. J. Immunol. 145, 1029–1036 (1990).
  CAS PubMed Google Scholar
• Neelapu, S. S. et al. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nature Med. 11, 986–991 (2005).
  Article CAS PubMed Google Scholar
• Inogés, S. et al. Feasibility of idiotype vaccination in relapsed B-cell malignancies. Haematologica 88, 1438–1440 (2003).
  PubMed Google Scholar
• Weng, W. K., Czerwinski, D., Timmerman, J., Hsu, F. J. & Levy, R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J. Clin. Oncol. 22, 4717–4724 (2004).
  Article CAS PubMed Google Scholar
• Weng, W. K., Czerwinski, D. & Levy, R. Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy. Blood 109, 951–953 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Hagenbeek, A. Monoclonal antibodies (update): CD20, rituximab. Hematol. Meeting Rep. 2, 50–51 (2008).
  Google Scholar